OPPORTUNITY

Offering a game changing, non-invasive diagnostic platform technology which saves lives through higher accuracy, faster results, and improved patient experience.

• KEY HIGHLIGHTS

  • Established 2004
  • Current patient trials underway at major NHS Hospitals throughout the UK
  • Large patent portfolio across the world, with further pending
  • Clinical Trial Partners in the US engaged and supportive
  • Includes the IPR for a specialised cell concentration & preservation collection device, a clinically validated Biomarker and utilises AI for automated analysis of results
  • 2MIllion Euro + £4.4M Investment to 2020
  • Initial core technology as a result of a £12million pound research project funded by Cancer Research UK and Cambridge University.
• Historic Valuation of business at circa £8 Million

Please download Notice For Sale for further information

Viewing Details

EXPRESSIONS OF INTEREST

• Interested parties will be required to sign a nondisclosure agreement (NDA) before further information is
• Expressions of interest are required by 12noon on Friday 12th August 2022 together with proof of funding with completion as soon possible

REQUESTS FOR AN NDA SHOULD BE SENT TO :-

RICHARD TEMPLE ([email protected])

0113 209 1052

or

ABBIE HICKMAN ([email protected])

0114 551 2527